Monday, July 11, 2016

Juno Therapeutics Inc. (JUNO) Sank After FDA Placed Phase 2 Study On Hold

Juno Therapeutics Inc. (JUNO) announced after the bell Thursday that the FDA has put its Phase II clinical trial of JCAR015 on a clinical hold after two patients died last week. The deaths followed the recent addition of fludarabine to the pre-conditioning regimen.

from RTT - Before the Bell http://ift.tt/29CzwkO
via IFTTT

No comments:

Post a Comment